GSK received FDA approval for Hibsago (bebiporvirsen), a chronic hepatitis B therapy positioned as a potential functional cure. The approval is notable not only for the new mechanism—targeting the viral genetic instructions used for replication—but also for the clinical development momentum tied to antisense-oligonucleotide platform science. The drug was licensed from Ionis Pharmaceuticals, linking the approval to Ionis’s earlier work in antisense therapeutics. GSK also framed the approval as part of a broader revenue ambition, signaling confidence that a differentiated HBV product could scale if durable response rates hold in follow-on data. For biotech stakeholders, the FDA nod reinforces continued regulatory openness to non-traditional modalities in infectious disease, particularly where viral persistence is the core therapeutic target rather than symptom control.